Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MacroGenics Signs Another Lucrative DART Deal with Janssen For $75m Up Front

Executive Summary

Janssen Biotech Inc. apparently likes what it's seen so far from the first bi-specific antibody that it licensed from MacroGenics Inc., because the Johnson & Johnson subsidiary obtained rights to a second asset from the Rockville, Maryland-based firm's Dual Affinity Re-Targeting (DART) platform.

You may also be interested in...



MacroGenics Regains DART Asset As Takeda Narrows Focus

MacroGenics has regained global rights to one of its DART compounds from Takeda, following a reprioritization of therapeutic areas by the Japanese firm that may open up new partnering opportunities in autoimmune disorders.

MacroGenics, Merck Seize Gastric Cancer Opportunity With Margetuximab, Keytruda Combo

MacroGenics Inc. will study the ability of margetuximab to enhance the immune system's destruction of HER2-positive tumors in a Phase Ib/II clinical trial to evaluate the monoclonal antibody in combination with Merck & Co.'s PD-1 inhibitor Keytruda (pembrolizumab) in advanced gastric cancer.

Janssen, MacroGenics sign potential $575m+ licensing deal

Janssen Biotech, a unit of Johnson and Johnson, has struck a licensing deal with clinical-stage biopharma MacroGenics for the development of the latter firm's CD19-directed therapy, MGD011.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel